Actual Use Trial of Tadalafil 5 mg
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
2,212actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-30 | actual | When the study began enrolling |
| Primary completion | 2026-03-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-02 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Erectile Dysfunction
Intervention
- Combination product: Tadalafil 5 mg tablets with a digital tool. — also filed as Cialis 5 mg
Primary outcomes
what the primary-completion date above is the date OFThe proportion of inter-dosing intervals in which the recommended time between doses is followed
measured From the beginning of Use phase to end, at 120 days.
The proportion of all participants found to have a do not use (DNU) condition in the Medical Assessment who also received a DNU Outcome screen in the Health survey assessment
measured 1 day (completion of the enrollment interview)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed